Hologic Buys Interlace Medical for $125 Mln
Interlace Medical, which was backed by Baird Venture Partners, has been sold to Hologic for $125 million. Additional earn-out payments can take place over the next two years, a statement said. Framingham, Mass.-based Interlace is a medical device company that has developed the MyoSure, which is used to remove intrauterine fibroids and polyps. Interlace received $20.5 million in Series C financing in 2009 from investors including BVP, Spray Venture Partners and New Leaf Venture Partners. Baird Venture Partners is the U.S. VC fund of Baird Private Equity.
11 January 2011•3 mins read
